$NGEN News

Last published 13h ago

13h agoNGENNervGen Receives FDA Breakthrough Therapy Designation for NVG-291 in Chronic Spinal Cord InjuryGlobeNewswireMIAMI, Nov. 12, 2026 (GLOBE NEWSWIRE) -- NervGen (NASDAQ: NGEN), a late-stage clinical biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury (SCI) and other neurotraumatic and neurologic conditions, today announced that the U.S. Food and Drug Administration (FDA) has granted NVG-291 Breakthrough Therapy designation for the treatment of chronic trau ...
1mo agoNGENNervGen Announces First Participant Dosed in RESTORE, a Phase 3 Registrational Study Evaluating NVG-291 in Chronic Spinal Cord InjuryGlobeNewswireRESTORE is evaluating NVG-291’s potential to improve hand function and quality of life in individuals living with chronic cervical motor-incomplete spinal cord injuryStudy builds on functional improvements observed in
2mo agoNGENNervGen to Host Inaugural R&D Day on September 30, 2026GlobeNewswireR&D Day to feature an in-depth review of NVG-291, including its nonclinical and translational foundation, broader therapeutic potential, clinical data generated to date, perspectives from the SCI community, and the
3mo agoNGENNervGen Reports Second Quarter 2026 Financial Results and Provides Business UpdatesGlobeNewswireSite activation and screening for the Phase 3 RESTORE study is expected to begin in September 2026, with the first participant anticipated to be dosed shortly thereafter. Strengthened leadership team, appointing Keith
5mo agoNGENNervGen Announces Positive Independent, Blinded Biomechanical Gait Analyses Demonstrating Genuine Neural Recovery with NVG-291 in Phase 1b/2a CONNECT SCI StudyGlobeNewswireNVG-291 demonstrated statistically significant improvement in gait quality (p=0.0197), based on a Global Statistical Test integrating the established hallmarks of genuine neural recovery into a unified assessment of
5mo agoNGENNervGen Announces Pricing of US$60.0 Million Public Offering of SecuritiesGlobeNewswireVANCOUVER, British Columbia, May 21, 2026 (GLOBE NEWSWIRE) -- NervGen Pharma Corp. ("NervGen" or the "Company") (NASDAQ:NGEN), a clinical-stage biopharmaceutical company developing first-in-class neuroreparative
5mo agoNGENNervGen Announces Proposed Public Offering of SecuritiesGlobeNewswireThe Base Shelf Prospectus is, and the Prospectus Supplement will be accessible within two business days, through SEDAR+ VANCOUVER, British Columbia, May 21, 2026 (GLOBE NEWSWIRE) -- NervGen Pharma Corp. ("NervGen" or
5mo agoNGENNervGen Reports First Quarter 2026 Financial Results and Provides Business UpdatesGlobeNewswireCompleted successful FDA End-of-Phase 2 meeting, reaching alignment on the study parameters of RESTORE, a registrational study of NVG-291 in chronic tetraplegia, with site activation underway and study initiation on
6mo agoNGENNervGen Pharma Strengthens Leadership Team with Appointment of Keith Vendola as Chief Financial OfficerGlobeNewswireVANCOUVER, British Columbia, April 27, 2026 (GLOBE NEWSWIRE) -- NervGen Pharma Corp. ("NervGen" or the "Company") (NASDAQ:NGEN), a clinical-stage biopharmaceutical company developing first-in-class neuroreparative
7mo agoNGENNervGen Pharma to Participate in the H.C. Wainwright "HCW@Home" Series and the 2026 Bloom Burton & Co. Healthcare Investor ConferenceGlobeNewswireVANCOUVER, British Columbia, April 13, 2026 (GLOBE NEWSWIRE) -- NervGen Pharma Corp. ("NervGen" or the "Company") (NASDAQ:NGEN), a clinical-stage biopharmaceutical company developing first-in-class neuroreparative
7mo agoNGENNervGen Pharma Announces Successful End-of-Phase 2 Meeting and FDA Alignment on RESTORE, a Phase 3 Registrational Study of NVG-291 for Chronic TetraplegiaGlobeNewswireAlignment with the FDA across proposed study parameters of RESTORE, a 16-week registrational study evaluating NVG-291 in chronic tetraplegia.Primary endpoint will be the change from baseline in GRASSP Quantitative
7mo agoNGENNervGen Pharma Reports Full Year 2025 Financial Results and Provides Business UpdatesGlobeNewswireCompleted End-of-Phase 2 meeting with the FDA; Company expects to provide a regulatory update in early 2Q 2026 and remains on track to initiate a Phase 3 study in chronic tetraplegia in mid-2026. Company expects to
8mo agoNGENNervGen Pharma Announces Voluntary Delisting from TSX Venture ExchangeGlobeNewswireThe Company's common shares will continue to trade on Nasdaq under the symbol "NGEN"No action is required; all shareholders, including Canadian shareholders, will continue to maintain full trading access on Nasdaq
8mo agoNGENNervGen Pharma Appoints Shamim Ruff as Chief Regulatory Affairs Officer and Christine McSherry as SVP, Patient Advocacy and Clinical AffairsGlobeNewswireVANCOUVER, British Columbia, March 04, 2026 (GLOBE NEWSWIRE) -- NervGen Pharma Corp. ("NervGen" or the "Company") (TSXV:NGEN) (NASDAQ:NGEN), a clinical-stage biopharmaceutical company developing first-in-class
8mo agoNGENNervGen Pharma to Participate at Upcoming Investor ConferencesGlobeNewswireVANCOUVER, British Columbia, Feb. 18, 2026 (GLOBE NEWSWIRE) -- NervGen Pharma Corp. ("NervGen" or the "Company") (TSXV:NGEN) (NASDAQ:NGEN), a clinical-stage biopharmaceutical company developing first-in-class
9mo agoNGENNervGen Pharma Announces Retirement of Chief Financial Officer, Bill AdamsGlobeNewswireVANCOUVER, British Columbia, Feb. 12, 2026 (GLOBE NEWSWIRE) -- NervGen Pharma Corp. ("NervGen" or the "Company") (TSXV:NGEN) (NASDAQ:NGEN), a clinical-stage biopharmaceutical company developing first-in-class
9mo agoNGEN NGENFNervGen Pharma to Present at Unite2Fight Paralysis' 20th Annual Science and Advocacy SymposiumGlobeNewswireAdam Rogers, MD, President and Chief Executive Officer of NervGen to present and discuss clinical data from the Phase 1b/2a CONNECT SCI Study demonstrating durable improvement in function, independence, and quality of
9mo agoNGEN NGENFNervGen Pharma Appoints Adam Rogers as Chief Executive Officer to Continue Leading the Company's Growth and Execution of Its Mission in Spinal Cord InjuryGlobeNewswireVANCOUVER, British Columbia, Feb. 09, 2026 (GLOBE NEWSWIRE) -- NervGen Pharma Corp. ("NervGen" or the "Company") (TSXV:NGEN) (NASDAQ:NGEN), a clinical-stage biopharmaceutical company developing first-in-class
10mo agoNGENF NGENNervGen Pharma Begins Trading on Nasdaq TodayGlobeNewswireVANCOUVER, British Columbia, Jan. 08, 2026 (GLOBE NEWSWIRE) -- NervGen Pharma Corp. ("NervGen" or the "Company") (TSXV:NGEN) (NASDAQ:NGEN), a clinical-stage biopharmaceutical company developing first-in-class
9y agoAPRI NGENInnovus Pharma Expands its Executive Management Team with the Addition of Randy Berholtz as its Executive Vice President, Corporate Development and General CounselBusiness WireSAN DIEGO--(BUSINESS WIRE)--Innovus Pharmaceuticals, Inc. ("Innovus Pharma") (OTCQB Venture Market: INNV), an emerging commercial stage pharmaceutical company that delivers safe, innovative and effective over-the-counter medicine and consumer care products to improve men’s and women’s health and respiratory diseases, today announced that Randy Berholtz will join the management team as Executive Vi ...